{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:30:10Z","timestamp":1793298610469,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00063-018-0406-1","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T09:57:39Z","timestamp":1517997459000},"page":"143-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Urosepsis"],"prefix":"10.1007","volume":"113","author":[{"given":"Mathias W.","family":"Pletz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"406_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","volume":"193","author":"C Fleischmann","year":"2016","unstructured":"Fleischmann C, Scherag A, Adhikari NK et al (2016) Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193:259\u2013272","journal-title":"Am J Respir Crit Care Med"},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1586\/eri.12.50","volume":"10","author":"GS Martin","year":"2012","unstructured":"Martin GS (2012) Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 10:701\u2013706","journal-title":"Expert Rev Anti Infect Ther"},{"key":"406_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00134-006-0517-7","volume":"33","author":"C Engel","year":"2007","unstructured":"Engel C, Brunkhorst FM, Bone HG et\u00a0al (2007) Epidemiology of sepsis in Germany: results from a\u00a0national prospective multicenter study. Intensive Care Med 33:606\u2013618","journal-title":"Intensive Care Med"},{"key":"406_CR4","doi-asserted-by":"publisher","first-page":"9028924","DOI":"10.1155\/2016\/9028924","volume":"2016","author":"XH Qiang","year":"2016","unstructured":"Qiang XH, Yu TO, Li YN et\u00a0al (2016) Prognosis risk of urosepsis in critical care medicine: a prospective observational study. Biomed Res Int 2016:9028924","journal-title":"Biomed Res Int"},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801\u2013810","journal-title":"JAMA"},{"key":"406_CR6","series-title":"AWMF Leitlinie AWMF RegNo 082-006","volume-title":"S2k Leitline: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen be Erwachsenen-Update 2017","author":"KF Bodmann","year":"2017","unstructured":"Bodmann KF, Grabein B, EDP-E-GFC EV (2017) S2k Leitline: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen be Erwachsenen-Update 2017. AWMF Leitlinie AWMF RegNo 082-006."},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00345-015-1722-1","volume":"34","author":"Z Tandogdu","year":"2016","unstructured":"Tandogdu Z, Bartoletti R, Cai T et\u00a0al (2016) Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003\u20132013. World J Urol 34:1193\u20131200","journal-title":"World J Urol"},{"key":"406_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archinte.1979.03630380056019","volume":"139","author":"PJ Demuth","year":"1979","unstructured":"Demuth PJ, Gerding DN, Crossley K (1979) Staphylococcus aureus bacteriuria. Arch Intern Med 139:78\u201380","journal-title":"Arch Intern Med"},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ Hal Van","year":"2012","unstructured":"Van Hal SJ, Jensen SO, Vaska VL et\u00a0al (2012) Predictors of mortality in staphylococcus aureus bacteremia. Clin Microbiol Rev 25:362\u2013386","journal-title":"Clin Microbiol Rev"},{"key":"406_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/1471-2334-10-225","volume":"10","author":"S Chihara","year":"2010","unstructured":"Chihara S, Popovich KJ, Weinstein RA et al (2010) Staphylococcus aureus bacteriuria as a\u00a0prognosticator for outcome of staphylococcus aureus bacteremia: a\u00a0case-control study. BMC Infect Dis 10:225","journal-title":"BMC Infect Dis"},{"key":"406_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285\u2013292","journal-title":"Clin Infect Dis"},{"key":"406_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/jac\/dkt108","volume":"68","author":"JL Nissen","year":"2013","unstructured":"Nissen JL, Skov R, Knudsen JD et al (2013) Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible staphylococcus aureus bacteraemia: a\u00a0retrospective, propensity-score-adjusted case-control and cohort analysis. J\u00a0Antimicrob Chemother 68:1894\u20131900","journal-title":"J Antimicrob Chemother"},{"key":"406_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2017.05.031","volume":"169","author":"S Weis","year":"2017","unstructured":"Weis S, Carlos AR, Moita MR et\u00a0al (2017) Metabolic adaptation establishes disease tolerance to sepsis. Cell 169:1263\u20131275","journal-title":"Cell"},{"key":"406_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/NEJMoa1415236","volume":"372","author":"KM Kaukonen","year":"2015","unstructured":"Kaukonen KM, Bailey M, Pilcher D et\u00a0al (2015) Systemic inflammatory response syndrome criteria in defining severe sepsis. N\u00a0Engl J Med 372:1629\u20131638","journal-title":"N Engl J Med"},{"key":"406_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.2016.0288","volume":"315","author":"CW Seymour","year":"2016","unstructured":"Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:762\u2013774","journal-title":"JAMA"},{"key":"406_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1164\/rccm.201604-0854OC","volume":"195","author":"MM Churpek","year":"2017","unstructured":"Churpek MM, Snyder A, Han X et al (2017) Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med 195:906\u2013911","journal-title":"Am J Respir Crit Care Med"},{"key":"406_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W et\u00a0al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304\u2013377","journal-title":"Intensive Care Med"},{"key":"406_CR18","unstructured":"www.survivingsepsis.org . Zugegriffen: 14.12.2017"},{"key":"406_CR19","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc9328","volume":"14","author":"C Nieuwkoop Van","year":"2010","unstructured":"Van Nieuwkoop C, Bonten TN, Van\u2019t Wout JW et\u00a0al (2010) Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a\u00a0prospective observational study. Crit Care 14:R206","journal-title":"Crit Care"},{"key":"406_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1532-5415.2009.02175.x","volume":"57","author":"KP High","year":"2009","unstructured":"High KP, Bradley SF, Gravenstein S et al (2009) Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. J\u00a0Am Geriatr Soc 57:375\u2013394","journal-title":"J Am Geriatr Soc"},{"key":"406_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1086\/313896","volume":"31","author":"DC Norman","year":"2000","unstructured":"Norman DC (2000) Fever in the elderly. Clin Infect Dis 31:148\u2013151","journal-title":"Clin Infect Dis"},{"key":"406_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"J Rodriguez-Bano","year":"2012","unstructured":"Rodriguez-Bano J, Navarro MD, Retamar P et al (2012) beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a\u00a0post hoc analysis of prospective cohorts. Clin Infect Dis 54:167\u2013174","journal-title":"Clin Infect Dis"},{"key":"406_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","volume":"19","author":"R Leclercq","year":"2013","unstructured":"Leclercq R, Canton R, Brown DF et\u00a0al (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141\u2013160","journal-title":"Clin Microbiol Infect"},{"key":"406_CR24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","volume":"60","author":"PD Tamma","year":"2015","unstructured":"Tamma PD, Han JH, Rock C et al (2015) Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60:1319\u20131325","journal-title":"Clin Infect Dis"},{"key":"406_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a\u00a0randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661\u2013673","journal-title":"Lancet Infect Dis"},{"key":"406_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a\u00a0phase 3 randomized trial program. Clin Infect Dis 63:754\u2013762","journal-title":"Clin Infect Dis"},{"key":"406_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"},{"key":"406_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/jac\/dkw499","volume":"72","author":"C Staley","year":"2017","unstructured":"Staley C, Vaughn BP, Graiziger CT et al (2017) Gut-sparing treatment of urinary tract infection in patients at high risk of clostridium difficile infection. J\u00a0Antimicrob Chemother 72:522\u2013528","journal-title":"J Antimicrob Chemother"},{"key":"406_CR29","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00345-013-1218-9","volume":"32","author":"M Cek","year":"2014","unstructured":"Cek M, Tandogdu Z, Wagenlehner F et al (2014) Healthcare-associated urinary tract infections in hospitalized urological patients \u2013 a global perspective: results from the GPIU studies 2003\u20132010. World J Urol 32:1587\u20131594","journal-title":"World J Urol"},{"issue":"11","key":"406_CR30","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s00134-017-4782-4","volume":"43","author":"F Bloos","year":"2017","unstructured":"Bloos F, Ruddel H, Thomas-Ruddel D et al (2017) Effect of a\u00a0multifaceted educational intervention for anti-infectious measures on sepsis mortality: a\u00a0cluster randomized trial. Intensive Care Med 43(11):1602\u20131612. https:\/\/doi.org\/10.1007\/s00134-017-4782-4","journal-title":"Intensive Care Med"},{"key":"406_CR31","first-page":"317","volume":"83","author":"W Hofmann","year":"1990","unstructured":"Hofmann W (1990) Urosepsis and uroseptic shock. Z\u00a0Urol Nephrol 83:317\u2013324","journal-title":"Z Urol Nephrol"},{"key":"406_CR32","first-page":"837","volume":"112","author":"NM Dreger","year":"2015","unstructured":"Dreger NM, Degener S, Ahmad-Nejad P et al (2015) Urosepsis \u2013 etiology, diagnosis, and treatment. Dtsch Arztebl Int 112:837\u2013847 (quiz 848)","journal-title":"Dtsch Arztebl Int"},{"key":"406_CR33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00120-010-2253-4","volume":"49","author":"FM Wagenlehner","year":"2010","unstructured":"Wagenlehner FM, Lichtenstern C, Weigand MA et\u00a0al (2010) Urosepsis and treatment. Urologe A 49:618\u2013622","journal-title":"Urologe A."},{"key":"406_CR34","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJMoa010307","volume":"345","author":"E Rivers","year":"2001","unstructured":"Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N\u00a0Engl J Med 345:1368\u20131377","journal-title":"N Engl J Med"},{"key":"406_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13054-016-1288-3","volume":"20","author":"HB Nguyen","year":"2016","unstructured":"Nguyen HB, Jaehne AK, Jayaprakash N et al (2016) Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE. Crit Care 20:160","journal-title":"Crit Care"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-018-0406-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-018-0406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-018-0406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:18:05Z","timestamp":1751375885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-018-0406-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1007\/s00063-018-0406-1","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]},"assertion":[{"value":"7 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.W.\u00a0Pletz hat an nationalen und internationalen Advisory Boards von Pfizer, Novartis, Basilea, Infectopharm und Cubist teilgenommen und Vortragshonorare dieser Firmen erhalten. S.\u00a0Weis hat Vortragshonorare von MSD und Infectopharm erhalten. C.\u00a0Forstner gibt an, Vortragshonorare von Pfizer, MSD, Basilea und Gilead erhalten zu haben. F.\u00a0Wagenlehner wurde honoriert f\u00fcr Beratert\u00e4tigkeit und erhielt Studienunterst\u00fctzung (Drittmittel) von den Firmen Achaogen, Astellas, AstraZeneca, Bionorica, Calixa Pharmaceuticals, Cerexa Pharmaceuticals, Cubist Pharmaceuticals, LEO, MSD, Pfizer, Rempex Pharmaceuticals, Rosen Pharma, Shionogi und Vifor Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}